JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267312

Human FUK knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

FCSK KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 11 and 1 bp deletion in exon 11 and 25 bp deletion in exon 11.

View Alternative Names

1110046B12Rik, FLJ39408, FUK_HUMAN, Fucokinase, L-fucose kinase

3 Images
Sanger Sequencing - Human FUK knockout HEK-293T cell line (AB267312)
  • Sanger seq

Unknown

Sanger Sequencing - Human FUK knockout HEK-293T cell line (AB267312)

Allele-3 : 1 bp deletion in exon 11.

Sanger Sequencing - Human FUK knockout HEK-293T cell line (AB267312)
  • Sanger seq

Unknown

Sanger Sequencing - Human FUK knockout HEK-293T cell line (AB267312)

Allele-1 : 25 bp deletion in exon11

Sanger Sequencing - Human FUK knockout HEK-293T cell line (AB267312)
  • Sanger seq

Unknown

Sanger Sequencing - Human FUK knockout HEK-293T cell line (AB267312)

Allele-2 : 10 bp deletion in exon 11.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 11 and 1 bp deletion in exon 11 and 25 bp deletion in exon 11

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267312-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267312 Human FUK knockout HEK-293T cell line", "number":"AB267312-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267312-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267312 Human FUK knockout HEK-293T cell line", "number":"AB267312-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
FCSK
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein FUK also known as fucokinase functions mechanistically as an enzyme that catalyzes the phosphorylation of L-fucose a monosaccharide involved in various metabolic processes. The molecular mass of FUK is approximately 131 kDa. FUK is primarily expressed in the liver but also in other tissues like the kidney and brain where it performs its enzymatic role as part of cellular metabolism.
Biological function summary

FUK plays a role in the salvage pathway of L-fucose metabolism. This pathway recycles free L-fucose into GDP-fucose which becomes essential for glycoprotein and glycolipid synthesis. FUK operates not as part of a larger protein complex but individually facilitating the utilization of fucose derived from dietary sources or breakdown of glycoproteins. The enzyme regulates intracellular concentrations of fucose impacting cell surface glycoconjugates important for cell signaling.

Pathways

FUK integrates into the fucose salvage pathway that links to glycosylation processes. This situates FUK within the larger context of glycan biosynthesis pathways where it intersects with enzymes such as GDP-fucose synthase. These pathways significantly influence the modification and function of proteins and lipids on cell surfaces affecting cellular communication and host-pathogen interactions.

FUK has connections to congenital disorders of glycosylation and cancer. Deficiencies in FUK enzyme activity can lead to disrupted fucosylation which contributes to clinical features seen in glycosylation disorders. In cancer abnormal fucose metabolism affects tumor progression and metastasis involving interactions with proteins such as fucosyltransferases which modify glycans on cell surfaces. Understanding FUK's role could provide insights into therapeutic approaches for glycol-related diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com